Belén Garijo, Chief Executive Officer of Sanofi, shared on LinkedIn:
“Strong performance today, stronger future tomorrow.
Today, Sanofi announced a major expansion of our longstanding Alliance with Regeneron, adding multiple next-generation, long-acting antibodies to our collaboration.
What started 20 years ago as a bold bet has become one of the most productive partnerships in our industry. Together, we have transformed how we treat diseases driven by type 2 inflammation and built a world-leading immunology business in the process.
What excites me most is that we are not resting on that achievement. We are doubling down to deliver therapies that will matter deeply to patients living with immune-mediated diseases and to build a pipeline that will define our future.
None of this happens without people. I want to deeply thank the Sanofi and Regeneron teams that made this possible, who have worked across companies, years, setbacks, and breakthroughs. You have built something extraordinary. And I can’t wait to see what we build next.
Here’s to the next 20 years.”
You can also read: Top 10 OncoGrants of the Week: Building the Research Pipeline, Advancing Access, and Backing Prevention
